| | Title | Author(s) | Year | View Count | | 1 |  | Evidence of serologic activity in chronic hepatitis B after surface antigen (HBsAg) seroclearance documented by conventional HBsAg assay | Seto, WK; Tanaka, Y; Wong, DKH; Lai, CL; Shinkai, N; Yuen, JCH; Tong, T; Fung, J; Hung, IFN; Yuen, MF | 2013 | 76 |
| 2 |  | HLA-DP and IL28 polymorphisms: Influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B | Seto, WKW; Wong, DKH; Kopaniszen, M; Proitsi, P; Sham, PC; Hung, IFN; Fung, JYY; Lai, CL; Yuen, RMF | 2013 | 28 |
| 3 | | Reduction of hepatitis B surface antigen levels and HBsAg seroclearance in chronic hepatitis B patients receiving 10 years of nucleoside analogue therapy | Seto, WKW; Wong, DKH; Fung, JYY; Huang, FY; Lai, CL; Yuen, RMF | 2013 | 11 |
| 4 | | Outcome of lamivudine-resistant chronic hepatitis B after up to 5 years of combination therapy with adefovir | Seto, WK; Liu, K; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, MF | 2012 | 77 |
| 5 |  | A large population histology study showing the lack of association between ALT elevation and significant fibrosis in chronic hepatitis B | Seto, WK; Lai, CL; Ip, PPC; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Yuen, MF | 2012 | 110 |
| 6 | | A large case-control study on the predictability of hepatitis B surface antigen levels three years before hepatitis B surface antigen seroclearance | Seto, WK; Wong, DKH; Fung, J; Hung, IFN; Fong, DYT; Yuen, JCH; Tong, T; Lai, CL; Yuen, MF | 2012 | 86 |
| 7 | | High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B | Seto, WK; Wong, DKH; Fung, J; Ip, PPC; Yuen, JCH; Hung, IFN; Lai, CL; Yuen, MF | 2012 | 103 |
| 8 | | Prevention of hepatitis B virus-related hepatocellular carcinoma with antiviral therapy. | Lai, CL; Yuen, RMF | 2012 | 60 |
| 9 | | High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen-Positive Chronic Hepatitis B | Pan, CQ; Tong, M; Kowdley, KV; Hu, K; Chang, T; Lai, C; Yoon, SK; Lee, SS; Cohen, D; Tang, H; Tsai, N | 2012 | 80 |
| 10 | | Acute-on-chronic liver failure in chronic hepatitis B | Seto, WK; Lai, CL; Yuen, MF | 2012 | 72 |
| 11 | | Serum hepatitis B surface antigen (HBsAg) kinetics in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B | Seto, WKW; Wong, DKH; Fung, JYY; Hung, IFN; Yuen, JCH; Tong, T; Lai, CL; Yuen, RMF | 2012 | 14 |
| 12 | | Future prevention and treatment of chronic hepatitis B infection | Seto, WK; Fung, J; Yuen, MF; Lai, CL | 2012 | 168 |
| 13 | | Clinicopathological and prognostic significance of serum and tissue Dickkopf-1 levels in human hepatocellular carcinoma | Tung, EKK; Mak, CKM; Fatima, S; Lo, RCL; Zhao, H; Zhang, C; Dai, H; Poon, RTP; Yuen, MF; Lai, CL; Li, JJ; Luk, JMC; Ng, IOL | 2011 | 224 |
| 14 | | Significance of HBV DNA levels at 12 weeks of telbivudine treatment and the 3 years treatment outcome | Seto, WK; Lai, CL; Fung, J; Wong, DKH; Yuen, JCH; Hung, IFN; Yuen, MF | 2011 | 212 |
| 15 | | Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection | Seto, WK; Yuen, MF; Fung, J; Lai, CL | 2011 | 363 |
| 16 | | To stop or not to stop: The quest for long-term viral suppression | Fung, J; Lai, CL; Yuen, MF | 2011 | 490 |
| 17 | | Current antiviral therapy of chronic hepatitis B: Efficacy and safety | Lam, YF; Yuen, MF; Seto, WK; Lai, CL | 2011 | 138 |
| 18 | | Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus Infection | Hsu, A; Lai, CL; Yuen, MF | 2011 | 140 |
| 19 | | The use of transient elastography in the management of chronic hepatitis B | Fung, J; Lai, CL; Seto, WK; Yuen, MF | 2011 | 122 |
| 20 | | A comprehensive HBV array for the detection of HBV mutants and genotype | Chan, K; Yam, I; Yuen, J; Yuen, MF; Lai, CL; Alexander, GJ; Chan, TK; Chan, V | 2011 | 186 |
|
